Answers are grounded in this paper and cite their sources.
Study evaluated incident risk of Parkinsonian disorders in older adults with iRBD and T2D, suggesting class-dependent risk.
Introduction and Objective: Isolated REM sleep behavior disorder (iRBD) is a prodromal marker of Parkinson’s disease (PD), Parkinsonism, and Lewy body dementia (LBD). This study evaluated whether the incident risk of PD, Parkinsonism, and LBD differed by glucose-lowering drug (GLD) class among patients with iRBD and type 2 diabetes. Methods: We conducted a target trial emulation using a retrospective active-comparator new-user design with Medicare fee-for-service claims among beneficiaries ≥65 years with iRBD and T2D. New users of glucagon-like peptide-1 receptor agonists (GLP-1RAs), dipeptidyl peptidase-4 inhibitors (DPP-4i), or sodium-glucose cotransporter-2 inhibitors (SGLT-2i) were identified. Hazard ratios for incident PD, Parkinsonism, PD/Parkinsonism composite, LBD, and a composite of all three were estimated using Cox proportional hazards models with stabilized inverse probability of treatment weighting to control for confounding. Results: A total of 148, 144, and 138 patients were included in the GLP-1RA vs. DPP-4i, GLP-1RA vs. SGLT-2i, and SGLT-2i vs. DPP-4i cohorts, respectively. Compared with DPP-4i use, GLP-1RA use was associated with a lower risk of PD (HR, 0.02; 95% CI, 0.001 - 0.20), parkinsonism (HR, 0.08; 95% CI, 0.01 - 0.96), and PD or parkinsonism composite (HR, 0.11; 95% CI, 0.01 to 0.83), but not LBD (HR, 0.45; 95% CI, 0.04 - 5.37). Similarly, compared with DPP-4i use, SGLT-2i use was associated with a lower risk of PD (HR, 0.03; 95% CI, 0.001 - 0.97), parkinsonism (HR, 0.02; 95% CI, 0.001 - 0.87), and their composite (HR, 0.02; 95% CI, 0.001 - 0.86), but not LBD (HR, 0.94; 95% CI, 0.17 - 5.17). No statistically significant differences were observed between GLP-1RA vs. SGLT-2i users. Conclusion: Among older adults with iRBD and T2D, incident risk of PD and parkinsonism varied by GLD class. GLP-1RAs and SGLT-2is were associated with lower risk than DPP-4is, while no differences were observed for LBD or between GLP-1RAs and SGLT-2is. Confirmation in larger studies with longer follow-up is needed. Disclosure P. Kotecha: Employee; Ended; Merck & Co., Inc.
No takes yet. Share an insight, caveat, or question.
Kotecha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: